Fungura uburyo bwiza bwo kuvura NSCLC hamwe na EGFR Yipimishije Iterambere

Kanseri y'ibihaha ikomeje kuba ikibazo cy’ubuzima ku isi, ikaza ku mwanya wa kabiri kanseri ikunze kugaragara. Muri 2020 honyine, ku isi hose habaruwe abantu barenga miliyoni 2.2. Kanseri y'ibihaha itari ntoya (NSCLC) ihagarariye ibice birenga 80% by'indwara zose za kanseri y'ibihaha, byerekana ko hakenewe ingamba zihamye zo kuvura.

Guhinduka kwa EGFR byagaragaye nkibuye rikomeza imfuruka mubuvuzi bwihariye bwa NSCLC. EGFR tyrosine kinase inhibitor (TKIs) itanga uburyo bwimpinduramatwara muguhagarika ibimenyetso bitera kanseri, kubuza gukura kwikibyimba, no guteza imbere kanseri ya kanseri - byose bikagabanya kwangirika kwingirangingo nzima.

Amabwiriza akomeye yubuvuzi, harimo na NCCN, ubu ategeka kwipimisha mutation ya EGFR mbere yo gutangiza imiti ya TKI, kwemeza ko abarwayi beza bahabwa imiti iboneye kuva mbere.

Guhinduka kwa EGFR byagaragaye nkibuye rikomeza imfuruka mubuvuzi bwihariye bwa NSCLC. EGFR tyrosine kinase inhibitor (TKIs) itanga uburyo bwimpinduramatwara muguhagarika ibimenyetso bitera kanseri, kubuza gukura kwikibyimba, no guteza imbere kanseri ya kanseri - byose bikagabanya kwangirika kwingirangingo nzima.

Amabwiriza akomeye yubuvuzi, harimo na NCCN, ubu ategeka kwipimisha mutation ya EGFR mbere yo gutangiza imiti ya TKI, kwemeza ko abarwayi beza bahabwa imiti iboneye kuva mbere.

Kumenyekanisha Ikiremwamuntu EGFR Gene 29 Igikoresho cyo Guhindura (Fluorescence PCR)
Kumenya neza ibyemezo byo kuvura ibyiringiro

Ibikoresho bya EGFR bya Macro & Micro-Test bifasha kumenya byihuse kandi nyabyo kumenya ihinduka ry’imiterere 29 ihindagurika kuri exons 18-21 muri tissue na biopsies - guha imbaraga abaganga kubuvuzi budasanzwe bafite ikizere.

Kuki GuhitamoMacro & Micro-Ikizamini'sIkizamini cya EGFR?

Iki gikoresho kigaragaza ihinduka ry’imiterere 29 ya EGFR muri exons 18-21 uhereye ku ngingo cyangwa mu maraso y’abarwayi ba NSCLC, ikubiyemo ibiyobyabwenge ndetse n’ahantu ho kurwanya indwara kugira ngo bayobore ikoreshwa ry’ibiyobyabwenge nka gefitinib na osimertinib.

1. 1.Iterambere rya ARMS Ikoranabuhanga: Yongerewe ARMS hamwe na patenti wongeyeho patenti kugirango bisobanuke neza;
2. 2.Gukungahaza kwa Enzymatique: Kugabanya imiterere yubwoko bwishyamba ukoresheje igogorwa ryimisemburo, kunoza neza kumenya no kugabanya amplification idasanzwe bitewe na genomique yo hejuru;
3. 3. Guhagarika ubushyuhe: Ongeraho ibyiciro byubushyuhe bwihariye mubikorwa bya PCR, kugabanya kudahuza no kongera kumenya neza;
4. 4.Uburemere bukabije: Kumenya ihinduka rito nka 1% ihinduka;
5. 5.Ibisobanuro Byukuri: Igenzura ryimbere hamwe na enzyme ya UNG kugabanya ibisubizo byibinyoma;
6. 6.Ibikorwa: Ibisubizo bifatika muminota 120
7. 7.Urugero rwibintu bibiri - Byakoreshejwe neza kubice byombi hamwe namaraso, bitanga ihinduka mubikorwa byubuvuzi
8. 8.Ubwuzuzanye bwagutse: Bihujwe cyane nibikoresho rusange bya PCR ku isoko;
9. 9.Ubuzima bwubuzima: amezi 12.

Kuyobora Ubuvuzi ufite Icyizere
Igikoresho gifasha kugwiza ibyavuye mu mavuriro no gukomeza imbere yo guhangana na sensibilité ikomeye kandi ihindagurika.

Kwagura Ubusobanuro bwawe bwa Oncology Portfolio
Shakisha uburyo bwuzuye bwibisubizo bya mutation kuri KRAS, BRAF, ROS1, ALK, BCR-ABL, TEL-AML1, nibindi byinshi - byose bigamije gushyigikira ubuvuzi bwuzuye bwa biomarker.

Wige byinshi:https://www.mmtest.com/ubumenyi/

Contact our team: marketing@mmtest.com